Asia: Food, Drugs, Healthcare, Life Sciences

쓰촨성이 중점 산업단지와 지역에 20개의 지식재산 서비스거점을 구축하여 기업 맞춤형 공공서비스를 확대하고 있다. 루저우시를 중심으로 백주, 의약건,

India's life sciences regulatory landscape in July 2026 saw major developments across pharmaceuticals, medical devices, and healthcare regulation. Key changes included the draft National Pharmacy Commission Bill proposing to replace the 80-year-old Pharmacy Act, CDSCO's final guidance on Medical Device Software establishing clear market access pathways, and stricter controls on high-alcohol oral formulations under Schedule H1.

The Asia-Pacific Economic Cooperation held a High-Level Policy Dialogue on Agricultural Biotechnology in Dalian, China, where participants explored how genome technologies are transforming food production across the region. Experts demonstrated innovations ranging from fish bred with fewer bones to rice varieties designed for diabetic populations, while addressing the critical challenge of public perception and regulatory frameworks. The dialogue emphasized science-based regulation and consumer education as

The NSW Civil and Administrative Tribunal (Tribunal) has suspended a specialist surgeon’s registration for six months following serious deficiencies in her surgical care, colonoscopy procedures, post-operative management and record-keeping.

On August 5, 2026, the Consumer Case Division of Thailand’s Civil Court rendered a judgment in a case involving a beauty clinic that advertised acne scar treatments using claims that the clinic was operated by a specialist physician and that the treatment, allegedly involving stem cell technology, could permanently remove acne scars.

An analysis of cross-border healthcare-data transfers under India’s Digital Personal Data Protection framework and the GDPR, examining consent, sensitive health information, processor obligations, transfer safeguards, localisation and regulatory risk.

The recent spate of inspections and raids conducted by the Food and Drug Administration (FDA) and the Food Safety and Standards Authority of India (FSSAI) across Maharashtra has triggered a wider debate on the balance between regulatory enforcement and procedural fairness. Several prominent restaurants, hotels and food establishments found themselves facing suspension orders, stop-business notices and threats of closure allegedly on account of hygiene discrepancies and alleged violations of food safety norms.

On 7 August 2026, the Delhi High Court stayed an order of the Food Safety and Standards Authority of India (“FSSAI”) prohibiting Dabur India Limited from selling certain food products carrying claims such as “100% Pure”, “100% Natural” and “100% Organic”. Hon’ble Justice Amit Mahajan (Delhi High Court) held that the prohibition ought not to have been passed without an opportunity of hearing. That order captures the season. In recent weeks, the regulator has intensified its enforcement measures to ensure compliance with the Food Safety and Standards Act, 2006, and the courts have begun to ask how far it may go.

The Food Safety and Standards Authority of India (“FSSAI”) has, over the course of late May 2025, taken two connected regulatory steps aimed at curbing misleading claims on packaged food labels. First, FSSAI issued a formal advisory to all Food Business Operators (“FBOs”) directing them to discontinue the use of the term “100%” on food labels, packaging, and promotional material. Second, and consistent with the concerns underlying that advisory, FSSAI issued a detailed notice to a confectionery company in India, flagging specific instances of non-compliant labelling and misleading claims across several of its product lines.